
Blanca E Ocampo-GarcÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5187244/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multimeric System of ^{99m} Tc-Labeled Gold Nanoparticles Conjugated to c[RGDfK(C)] for Molecular Imaging of Tumor α(v)β(3) Expression. Bioconjugate Chemistry, 2011, 22, 913-922.	3.6	114
2	Molecular Targeting Radiotherapy with Cyclo-RGDfK(C) Peptides Conjugated to ¹⁷⁷ Lu-Labeled Gold Nanoparticles in Tumor-Bearing Mice. Journal of Biomedical Nanotechnology, 2014, 10, 393-404.	1.1	95
3	99mTc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. Nuclear Medicine and Biology, 2011, 38, 1-11.	0.6	79
4	Multifunctional targeted therapy system based on ^{99m} Tc/ ¹⁷⁷ Luâ€labeled gold nanoparticlesâ€Tat(49–57)â€Lys ³ â€bombesin internalized in nuclei of prostate cancer cells. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 663-671.	1.0	73
5	Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis. Materials Science and Engineering C, 2019, 103, 109766.	7.3	63
6	Clinical translation of a PSMA inhibitor for 99m Tc-based SPECT. Nuclear Medicine and Biology, 2017, 48, 36-44.	0.6	52
7	Gold nanoparticles conjugated to [Tyr3]Octreotide peptide. Biophysical Chemistry, 2008, 138, 83-90.	2.8	50
8	Lys ³ -Bombesin Conjugated to ^{99m} Tc-Labelled Gold Nanoparticles for <i>In Vivo</i> Gastrin Releasing Peptide-Receptor Imaging. Journal of Biomedical Nanotechnology, 2010, 6, 375-384.	1.1	47
9	Hydrogels based on poly(ethylene glycol) as scaffolds for tissue engineering application: biocompatibility assessment and effect of the sterilization process. Journal of Materials Science: Materials in Medicine, 2016, 27, 176.	3.6	44
10	Biodegradable poly(D,L-lactide-co-glycolide)/poly(L-γ-glutamic acid) nanoparticles conjugated to folic acid for targeted delivery of doxorubicin. Materials Science and Engineering C, 2017, 76, 743-751.	7.3	43
11	177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer. Materials Science and Engineering C, 2019, 105, 110043.	7.3	42
12	Multifunctional Radiolabeled Nanoparticles for Targeted Therapy. Current Medicinal Chemistry, 2013, 21, 124-138.	2.4	41
13	¹⁷⁷ Lu-Dendrimer Conjugated to Folate and Bombesin with Gold Nanoparticles in the Dendritic Cavity: A Potential Theranostic Radiopharmaceutical. Journal of Nanomaterials, 2016, 2016, 1-11.	2.7	40
14	Fluorescent, Plasmonic, and Radiotherapeutic Properties of the ¹⁷⁷ Lu–Dendrimer-AuNP–Folate–Bombesin Nanoprobe Located Inside Cancer Cells. Molecular Imaging, 2017, 16, 153601211770476.	1.4	39
15	Antibacterial Efficacy of Gold and Silver Nanoparticles Functionalized with the Ubiquicidin (29–41) Antimicrobial Peptide. Journal of Nanomaterials, 2017, 2017, 1-10.	2.7	37
16	177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing $\hat{l} \pm (\hat{l} \frac{1}{2})\hat{l}^2(3)$ integrins. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 140-148.	1.0	31
17	Kit for preparation of multimeric receptor-specific 99mTc-radiopharmaceuticals based on gold nanoparticles. Nuclear Medicine Communications, 2011, 32, 1095-1104.	1.1	29
18	Laser Heating of Gold Nanospheres Functionalized with Octreotide: <i>In Vitro</i> Effect on HeLa Cell Viability. Photomedicine and Laser Surgery, 2013, 31, 17-22.	2.0	28

#	Article	IF	CITATIONS
19	99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients. Nuclear Medicine and Biology, 2017, 52, 1-6.	0.6	28
20	Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with ¹⁷⁷ Lu and Conjugated to Peptides. Current Radiopharmaceuticals, 2015, 8, 150-159.	0.8	28
21	Synthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic Effect on Breast Cancer Cells. Polymers, 2019, 11, 1572.	4.5	27
22	Synthesis and evaluation of Lys 1 (α,γ-Folate)Lys 3 (177 Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer. Applied Radiation and Isotopes, 2016, 107, 214-219.	1.5	26
23	Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms. Current Pharmaceutical Design, 2012, 18, 1098-1106.	1.9	25
24	Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging. Journal of Nanoscience and Nanotechnology, 2015, 15, 4159-4169.	0.9	24
25	Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging. Nuclear Medicine Communications, 2014, 35, 423-432.	1.1	23
26	Preparation and preclinical evaluation of 68Ga-iPSMA-BN as a potential heterodimeric radiotracer for PET-imaging of prostate cancer. Journal of Radioanalytical and Nuclear Chemistry, 2018, 318, 2097-2105.	1.5	19
27	Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Nuclear Medicine Communications, 2019, 40, 278-286.	1.1	19
28	[99mTc-HYNIC-N-dodecylamide]: a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging. Nanoscale, 2019, 11, 541-551.	5.6	18
29	Synthesis and preclinical evaluation of the 99mTc-/177Lu-CXCR4-L theranostic pair for in vivo chemokine-4 receptor-specific targeting. Journal of Radioanalytical and Nuclear Chemistry, 2020, 324, 21-32.	1.5	16
30	Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging. Molecules, 2022, 27, 264.	3.8	16
31	177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer. Contrast Media and Molecular Imaging, 2018, 2018, 1-10.	0.8	15
32	Multifunctional Targeted Radiotherapy System for Induced Tumours Expressing Gastrin-releasing Peptide Receptors. Current Nanoscience, 2012, 8, 193-201.	1.2	14
33	Engineered Multifunctional RGD-Gold Nanoparticles for the Detection of Tumour-Specific <1>ݱ(<1>ݽ)<1>ݲ(3) Expression: Chemical Characterisation and Ecotoxicological Risk Assessment. Journal of Biomedical Nanotechnology, 2012, 8, 991-999.	1.1	14
34	Improved radiopharmaceutical based on 99mTc-Bombesin–folate for breast tumour imaging. Nuclear Medicine Communications, 2016, 37, 377-386.	1.1	14
35	In vitro and in vivo synergistic effect of radiotherapy and plasmonic photothermal therapy on the viability of cancer cells using 177Lu–Au-NLS-RGD-Aptamer nanoparticles under laser irradiation. Journal of Radioanalytical and Nuclear Chemistry, 2018, 318, 1913-1921.	1.5	14
36	Click chemistry for [99mTc(CO)3] labeling of Lys3-bombesin. Applied Radiation and Isotopes, 2010, 68, 2274-2278.	1.5	13

#	Article	IF	CITATIONS
37	Design and biological evaluation of 99mTc-N2S2-Tat(49–57)-c(RGDyK): A hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins. Nuclear Medicine and Biology, 2013, 40, 481-487.	0.6	13
38	177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: synthesis and assessment of the ability to target the prostate specific membrane antigen. Journal of Radioanalytical and Nuclear Chemistry, 2018, 318, 2059-2066.	1.5	13
39	Synthesis, chemical and biochemical characterization of Lu2O3-iPSMA nanoparticles activated by neutron irradiation. Materials Science and Engineering C, 2020, 117, 111335.	7.3	12
40	Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen. Scientific Reports, 2020, 10, 9313.	3.3	11
41	Drug Delivery Systemsâ€Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy. Macromolecular Bioscience, 2021, 21, e2000362.	4.1	11
42	Development of ¹⁷⁷ Lu-DN(C19)-CXCR4 Ligand Nanosystem for Combinatorial Therapy in Pancreatic Cancer. Journal of Biomedical Nanotechnology, 2021, 17, 263-278.	1.1	11
43	Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical. Journal of Radioanalytical and Nuclear Chemistry, 2017, 314, 2201-2207.	1.5	10
44	[68Ga]Ga-iPSMA-Lys3-Bombesin: Biokinetics, dosimetry and first patient PET/CT imaging. Nuclear Medicine and Biology, 2021, 96-97, 54-60.	0.6	10
45	Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications. Pharmaceutics, 2021, 13, 1123.	4.5	10
46	Synthesis and Biochemical Evaluation of Samarium-153 Oxide Nanoparticles Functionalized with iPSMA-Bombesin Heterodimeric Peptide. Journal of Biomedical Nanotechnology, 2020, 16, 689-701.	1.1	10
47	Cyclization of RGD peptide sequences via the macrocyclic chelator DOTA for integrin imaging. Dalton Transactions, 2012, 41, 14051.	3.3	9
48	Hybrid (2D/3D) Dosimetry of Radiolabeled Gold Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer. Contrast Media and Molecular Imaging, 2020, 2020, 1-7.	0.8	9
49	Synthesis and in vitro evaluation of an antiangiogenic cancer-specific dual-targeting 177Lu-Au-nanoradiopharmaceutical. Journal of Radioanalytical and Nuclear Chemistry, 2017, 314, 1337-1345.	1.5	8
50	Multimeric System of RGD-Grafted PMMA-Nanoparticles as a Targeted Drug- Delivery System for Paclitaxel. Current Pharmaceutical Design, 2017, 23, 3415-3422.	1.9	8
51	^{99m} Tc-CXCR4-L for Imaging of the Chemokine-4 Receptor Associated with Brain Tumor Invasiveness: Biokinetics, Radiation Dosimetry, and Proof of Concept in Humans. Contrast Media and Molecular Imaging, 2020, 2020, 1-10.	0.8	8
52	Electron transfer reactions in rhodamine: Potential use in photodynamic therapy. Journal of Photochemistry and Photobiology A: Chemistry, 2021, 409, 113131.	3.9	8
53	Targeted Endoradiotherapy with Lu2O3-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image. Pharmaceutics, 2022, 14, 720.	4.5	8
54	Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer. Pharmaceutics, 2022, 14, 1095.	4.5	7

#	Article	IF	CITATIONS
55	[99mTc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities. Pharmaceuticals, 2022, 15, 729.	3.8	7
56	A freeze-dried kit formulation for the preparation of Lys 27 (99m Tc-EDDA/HYNIC)-Exendin(9-39)/ 99m Tc-EDDA/HYNIC-Tyr 3 -Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology, 2015, 42, 911-916.	0.6	6
57	Tumoral fibrosis effect on the radiation absorbed dose of 177Lu–Tyr3-octreotate and 177Lu–Tyr3-octreotate conjugated to gold nanoparticles. Applied Radiation and Isotopes, 2015, 100, 96-100.	1.5	6
58	Preparation and Characterization of a Tumor-Targeting Dual-Image System Based on Iron Oxide Nanoparticles Functionalized with Folic Acid and Rhodamine. Journal of Nanomaterials, 2017, 2017, 1-11.	2.7	6
59	Comparative Effect Between Laser and Radiofrequency Heating of RGD-Gold Nanospheres on MCF7 Cell Viability. Journal of Nanoscience and Nanotechnology, 2015, 15, 9840-9848.	0.9	5
60	Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy. Current Medicinal Chemistry, 2020, 27, 7032-7047.	2.4	5
61	225Ac-rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-Bl Proteins. Molecules, 2022, 27, 2156.	3.8	5
62	Physicochemical behaviour of a dinuclear uranyl complex formed with an octaphosphinoylated para-tert-butylcalix[8]arene. Spectroscopic studies in solution and in the solid state. Polyhedron, 2017, 123, 75-89.	2.2	4
63	99mTc-exendin(9-39)/octreotide. Nuclear Medicine Communications, 2017, 38, 912-918.	1.1	4
64	Preclinical dosimetric studies of ¹⁷⁷ Luâ€scFvD2B and comparison with ¹⁷⁷ Luâ€PSMAâ€617 and ¹⁷⁷ Luâ€iPSMA endoradiotherapeutic agents. Medical Physi 2021, 48, 4064-4074.	cs,3.0	3
65	[99mTc]Tc-iFAP Radioligand for SPECT/CT Imaging of the Tumor Microenvironment: Kinetics, Radiation Dosimetry, and Imaging in Patients. Pharmaceuticals, 2022, 15, 590.	3.8	3
66	Preclinical Biokinetic Modelling of Tc-99m Radiophamaceuticals Obtained from Semi-Automatic Image Processing. Journal of Medical and Biological Engineering, 2017, 37, 887-898.	1.8	2
67	Preparation and Dosimetry Assessment of ¹⁶⁶ Dy ₂ O ₃ / ¹⁶⁶ Ho ₂ O ₃ -iPSMA Nanoparticles for Targeted Hepatocarcinoma Radiotherapy. Journal of Nanoscience and Nanotechnology. 2021, 21, 5449-5458.	0.9	2
68	Targeted photodynamic therapy using reconstituted high-density lipoproteins as rhodamine transporters. Photodiagnosis and Photodynamic Therapy, 2021, 37, 102630.	2.6	2
69	IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery. Pharmaceutics, 2022, 14, 1060.	4.5	2
70	Biokinetics of [sup 99m]Tc-labeled gold nanoparticles conjugated to mannose for specific sentinel node detection. , 2010, , .		0
71	Preparation of Heterobivalent and Multivalent Radiopharmaceuticals to Target Tumors Over-Expressing Integrins. Methods in Pharmacology and Toxicology, 2015, , 69-92.	0.2	0
72	Dual-Targeted Therapy and Molecular Imaging with Radiolabeled Nanoparticles. Ecoproduction, 2019, , 201-219.	0.8	0